Skip to main content
PALI logo

Palisade Bio, Inc. (PALI) Stock: Price, Forecast & Analyst Target

Palisade Bio, Inc. (PALI) — MoonshotScore 28/100 (Weak band), calculated Nov 18, 2026. Price $0.9254 (-1.77%), as of the Nov 19, 2026 trading session; market cap $166M.

Educational signal · not a buy or sell recommendation · How to read this

$0.9254 −$0.0167 (-1.77%) Market Cap $166M

Palisade Bio, Inc. · PALI · NASDAQ

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies for gastrointestinal diseases.

Price as of Nov 19, 2026

Key Statistics

28 of 100

MoonshotScore v2 · Palisade Bio (PALI)

Weak
Business Quality Poor (19)
Financial Safety Sound (68)
Valuation Full (40)
Growth Durability Shrinking (16)
Momentum Slipping (30)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A strong balance sheet, but bottom-tier quality, stalling growth and a full valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Sound; Valuation: Full; Growth Durability: Shrinking; Momentum: Slipping.

  • quarterly revenue $500,000 (Q2 FY2026, quarter ended Jun 30, 2026)
  • EPS beat 2 of the last 8 reports
  • Altman Z 15.82 · Piotroski F 3

Holding back: weak fundamentals, soft growth, weak price trend

Helping: balance-sheet strength

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for PALI (57 recorded, newest six shown)
RecordedScoreBand
29Weak
29Weak
29Weak
29Weak
28Weak
28Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.9254
Change on the day-1.77%
52-week range$0.9254 – $2.86
Market capitalisation$166M—
Shares traded on the day2.74M

Price & events

Other perspectives

Council score for Palisade Bio (PALI): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Negative
Financial Safety Moderate
Valuation Neutral
Growth Durability Negative
Momentum Weak

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Unfavorable read

Read on: Sep 6, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Negative
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Strong
ROE Negative
Gross Margin Negative

Read on: May 2, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On May 2, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Palisade Bio (PALI), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Palisade Bio, Inc. (PALI) is listed on NASDAQ. It employs 14 people and is led by J. D. Finley. In Q2 FY2026 it reported revenue of $500,000 and net income of -$11M. The market values it at $166M.

2 · Latest results

What do the latest results show for Palisade Bio (PALI)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $500,000. Against analyst estimates the company has EPS beat 2 of the last 8 reports.

Quarterly income statement — 1 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026$500,000-$11M-$0.05 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Palisade Bio (PALI)?

Short answer · as of

The MoonshotScore pillars rate balance-sheet strength as strengths. What is holding it back is weak fundamentals, soft growth, weak price trend. The distress and quality screens read Altman Z 15.82 · Piotroski F 3. Trailing ratios: ROE -35.6% · ROA -36.9% · current ratio 20.16 · earnings yield -18.4% · free-cash-flow yield -13.1%.

Data-derived red flags

  • Listing risk — at $0.9254 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
  • Negative return on equity (-35.6%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
4 · What to check next?

What should you watch next at Palisade Bio (PALI)?

Short answer · as of

Current published price targets run low $2.00 · high $7.00 · consensus $4.50 · median $4.50 against a quoted price of $0.9254 (as of Nov 19, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Palisade Bio compare with its peers?

Short answer

Palisade Bio's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.28 Nov 18, 2026$552M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$3.06 Nov 19, 2026$258M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$11.25 Nov 18, 2026$102M82 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.26 Nov 18, 2026$85.5M82 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.89 Nov 18, 2026$169M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.88 Nov 19, 2026$178M69 5-pillar Nov 18, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$12.17 Nov 19, 2026$861M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.30 Nov 18, 2026$546M68 5-pillar Nov 18, 2026
SpyGlass Pharma, Inc. Common Stock (SGP) Same industry, near in market value$30.78 Nov 19, 2026$1.03B64 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$8.14 Nov 19, 2026$796M63 5-pillar Nov 18, 2026
Palisade Bio (PALI) — this page$0.9254$166M28

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$2.00 – $7.00
Consensus target
$4.50
Median target
$4.50

Consensus record · Captured .

Measured against a quoted price of $0.9254 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held PALI in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported PALI in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Palisade Bio (PALI)?

Read these with our analysis →

Investor Questions: PALI Stock

These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.

What does the MoonshotScore mean for PALI?

PALI carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is PALI a good stock to buy?

Stock Expert AI does not rate PALI buy, sell or hold. Palisade Bio, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the PALI stock price today?

The last price recorded for Palisade Bio, Inc. (PALI), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the PALI price target?

The analyst consensus price target for Palisade Bio, Inc. (PALI), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the key factors to evaluate for PALI?

Palisade Bio, Inc. (PALI) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. The company is focused on oral therapies, offering a potentially more convenient administration route compared to injectable alternatives. Not financial advice.

How frequently does PALI data refresh on this page?

PALI's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven PALI's recent stock price performance?

Palisade Bio, Inc. (PALI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on oral therapies for gastrointestinal diseases. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider PALI overvalued or undervalued right now?

Palisade Bio, Inc. (PALI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of PALI?

Fractional-share availability for Palisade Bio, Inc. (PALI) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 19 figures on this page — 11 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.